Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERGONAL vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pergonal (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from postmenopausal urine. It stimulates ovarian follicular growth and maturation in women and spermatogenesis in men by acting on specific gonadal receptors.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Induction of ovulation in patients with polycystic ovary disease or anovulatory infertility not due to primary ovarian failure,Stimulation of multiple follicular development in ovulatory patients undergoing assisted reproductive technologies (ART),Induction of spermatogenesis in men with hypogonadotropic hypogonadism (in combination with h CG)
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
Intramuscular administration: 75 IU daily for 7-12 days, then 5,000-10,000 IU h CG 24 hours after last dose.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Terminal elimination half-life approximately 24-36 hours; clinical context: supports daily dosing in ovulation induction protocols.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Menotropins are metabolized via proteolytic degradation in the liver and kidneys. The metabolic pathways involve hydrolysis into amino acids and smaller peptides.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal: 70-80% as unchanged drug and metabolites within 24 hours; biliary/fecal excretion accounts for <5%.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Approximately 10-15% bound to serum albumin.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Vd approximately 0.5-0.6 L/kg, indicating distribution limited to extracellular fluid.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Intramuscular: approximately 100% bioavailability; subcutaneous: approximately 80-90% relative to IM.
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No specific guidelines; use with caution in renal impairment as drug excretion may be reduced.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific Child-Pugh based modifications; use with caution in severe hepatic impairment.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not indicated for pediatric use; no weight-based guidelines established.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not typically used in elderly; consider age-related decline in ovarian response and increased risk of adverse events.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
Pergonal should only be used by physicians who are experienced in fertility disorders and in settings where monitoring of estradiol levels and follicular development through ultrasound is possible. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and is characterized by sudden ovarian enlargement, ascites, pleural effusion, oliguria, and thromboembolic events. Multiple births are increased.
None.
Ovarian hyperstimulation syndrome (OHSS),Thromboembolic events,Ovarian torsion,Ovarian enlargement,Multiple gestation,Ectopic pregnancy,Spontaneous abortion,Ovarian neoplasms (long-term use),Pulmonary complications (atelectasis, acute respiratory distress syndrome)
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Pituitary tumor,Ovarian cyst or enlargement of unknown origin,Abnormal vaginal bleeding of undetermined cause,Pregnancy,Sex hormone-dependent tumors (e.g., breast, uterus)
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No known food interactions. Maintain adequate hydration to help reduce the risk of OHSS; avoid excessive alcohol or caffeine as they may contribute to dehydration.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
Pergonal (menotropins) is a gonadotropin used for ovulation induction. In vitro studies show no evidence of teratogenicity; however, there is a risk of multiple gestation (20% twinning rate, higher order multiples less common). No specific fetal malformations are attributed to the drug. First trimester exposure is not associated with major congenital anomalies. Second and third trimester risks are minimal as the drug is not continued after pregnancy is achieved.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
No data available on excretion into breast milk. Pergonal is not indicated during breastfeeding. The M/P ratio is unknown. Due to the hormonal nature and potential for adverse effects in infants, breastfeeding is not recommended during therapy.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
No dosing adjustments are required in pregnancy because Pergonal is discontinued once pregnancy is confirmed. Treatment is typically stopped after ovulation and conception. Pharmacokinetic changes in pregnancy do not apply as the drug is not used during gestation.
Do not use in pregnancy. No dose recommendations available; contraindicated.
Pergonal (menotropins) is a human menopausal gonadotropin used for ovulation induction. Monitor estradiol levels and follicular growth via ultrasound to minimize ovarian hyperstimulation syndrome (OHSS) and multiple gestation. Administer IM only; do not use if solution is cloudy or contains particles. Concomitant use with Gn RH agonists may require dose adjustments. Discontinue if severe ovarian enlargement or pain occurs.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
This medication is injected into a muscle; your healthcare provider will show you how to prepare and give the injection.,You will need frequent blood tests and ultrasound exams to monitor your response to the medication and reduce risks.,The most common serious side effects are ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy. Notify your doctor immediately if you experience severe pelvic pain, bloating, nausea, vomiting, or rapid weight gain.,Store unused vials in the refrigerator; do not freeze. Protect from light. Discard any unused portion after opening.,Do not use if you are already pregnant or have ovarian cysts, abnormal vaginal bleeding, thyroid or adrenal disorders, or pituitary tumors.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERGONAL vs ANDEMBRY, answered by our medical review team.
PERGONAL is a Gonadotropin that works by Pergonal (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from postmenopausal urine. It stimulates ovarian follicular growth and maturation in women and spermatogenesis in men by acting on specific gonadal receptors.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERGONAL and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERGONAL is: Intramuscular administration: 75 IU daily for 7-12 days, then 5,000-10,000 IU h CG 24 hours after last dose.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERGONAL and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERGONAL is classified as Category C. Pergonal (menotropins) is a gonadotropin used for ovulation induction. In vitro studies show no evidence of teratogenicity; however, there is a risk of multiple gestation (20% twin. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.